Saturday, December 20, 2025 | 05:10 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
premium

The Phase 2 trials were conducted across Postgraduate Institute of Medical Education and Research, Chandigarh, All India Institute of Medical Sciences (AIIMS) Delhi, and AIIMS, Bhopal.

Sohini Das Mumbai
As the race to find treatment or vaccine for Covid-19 hots up, Ahmedabad-based Cadila Pharmaceuticals and the Council of Scientific and Industrial Research’s (CSIR’s) Sepsivac is all set to enter Phase 3 clinical trials after the earlier phase showed positive results. 

The public-private partnership trial-generated data will be soon presented before the country’s drug regulator to see if it can get emergency-use authorisation. 

“By July 15, we will have the necessary data from the Phase 2 trials and again approach the regulator to see if this drug can be given emergency-use authorisation in the wake of the pandemic. Meanwhile, we also have